drugset
drugset / Trial / NCT07317115

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

NCT07317115 ↗

Recruiting 20 enrolled GT Metabolic Solutions, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).

Timeline

Start
2026-03-18
Primary completion
2027-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 2.4 mg Subcutaneous

Indications

obesity disorder type 2 diabetes mellitus